endpoint Clinical has collaborated with THREAD to provide sponsors with a solution that can simplify decentralised clinical trials (DCT) operations and reduce study timelines.

While endpoint Clinical offers interactive response technology (IRT) for trials, THREAD provides technology and services for decentralised trials.

The new solution will adopt an ecosystem approach, which utilises the complete potential of key functions, including telehealth visits and direct-to-patient or home health shipping of trial medicines.

In addition, the approach is expected to allow engagement, compliance and retention of participants.

endpoint Clinical Global Sales vice-president Brad Cottreau said: “Adoption of DCT technologies that are capable of not only performing individually as best-in-class solutions but are also designed and engineered to be at optimal performance in an integrated clinical data mesh are the key to meeting demands and leading in the rapidly changing landscape of clinical trials.”

As part of the collaboration, the companies will facilitate a two-way combination for eConsent, screening, and randomisation, to support automation of fundamental workflows of the two platforms.

Specifically, the interfacing of systems affects sites since duplicate data entry is not required.

The integrated method also simplifies trial operations, including subject generation, screening, evaluations, randomisation and participant treatment visits.

Meanwhile, the two-way connection between the platforms facilitates data-driven, quick feedback to inform plans for enrolment, supply procurement, clinical operations, as well as data management.

When combined, this could lead to cleaner data and a rapid trial conclusion, endpoint Clinical noted.

THREAD CEO John Reites said: “As decentralised trials continue to propel global scalability and flexibility of clinical trials, THREAD partners with clients to ensure a seamless execution from study design to close-out via our single, comprehensive platform.

“Our collaboration with endpoint represents a new way to synchronise the real-world experience of the participant with the data at the site, resulting in one smooth continuum.”

Last month, THREAD entered a strategic collaboration with Almac Clinical Technologies to combine their respective technology platforms to reduce the risk of trial delays.